SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.
about
The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecinEffect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics studyAnalysis of the Active-Site Mechanism of Tyrosyl-DNA Phosphodiesterase I: A Member of the Phospholipase D SuperfamilyReplacement of the human topoisomerase linker domain with the plasmodial counterpart renders the enzyme camptothecin resistantChromosome-scale genetic mapping using a set of 16 conditionally stable Saccharomyces cerevisiae chromosomes.Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.Selective ploidy ablation, a high-throughput plasmid transfer protocol, identifies new genes affecting topoisomerase I-induced DNA damage.The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavageCDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin.Pleiotropic drug-resistance attenuated genomic library improves elucidation of drug mechanisms.A small organic compound enhances the religation reaction of human topoisomerase I and identifies crucial elements for the religation mechanism.Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast.Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death.Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
P2860
Q22009054-EF6F5518-1538-4FA7-B3D1-65F05E99C17CQ24810359-57815E6D-B21E-4DC7-8C66-1D2849E8E461Q27676072-A20E9187-5EEC-4D67-80BF-E493AB542E63Q28534477-CB6276D7-D75D-4071-A67B-F2BC23F193F7Q33373610-2043CC92-9564-4FD6-86A6-9DFC87D8023CQ33712882-1ED6EDBA-CF55-4BF5-B642-0F57838F0355Q33776558-20F1A576-79FB-40F5-B122-D141879C6F84Q35130480-05ACBD81-A45A-47D7-B025-08D264C4F8A5Q35172933-563429C7-A16E-4A7C-8FF7-EDB33EB5CB5CQ35651126-0B96548A-EED4-4E5F-913A-6FF37DF5A1EBQ35724882-8B71C3DF-12D7-4A5C-975B-B814D73399E4Q35779407-B359C243-2118-4385-8A46-3C3DC3FAEDCFQ36663311-14E835C5-290A-4B25-B305-090140B5F8FCQ36855683-2A1829E4-3884-47E6-9464-302F95434D5CQ37155139-4EFF8980-69E2-495B-80B9-0FEBFD3ADFBEQ37199784-43DFFE53-B77F-4BEB-A6DB-B0FC8A624851Q37257775-E6517678-80D1-428F-AD07-583726C60014Q37421089-911CDF4D-E5B5-44B9-89CB-37126BD64813Q38293789-44BB34D8-E273-4211-9380-731144EDB69AQ38351710-395C6A31-90A9-49AC-9EE2-5ED65E6E9143Q40605317-A02FFD4A-78C8-4240-A0C0-77A36C2279B9Q41912277-15090491-EBA3-4D9E-B6B6-5135FFE26A94Q42316506-6ED75A0B-31D8-4E72-8549-DC945BAD75CAQ42950337-FB23DC0B-EF78-4C88-BCAD-22BFCDE61DBBQ43250300-5AC0E92A-0E0A-49A3-B74B-77800813FC21Q44780529-CF920EC2-7E33-4DDB-AB7A-040AB1290E42Q45110862-7EA5170C-D303-43F0-A5B4-7890FDBA9A58Q53861588-B3C5D7A4-4281-4AD0-8093-33FAB8F36F57Q54051610-C142DE0A-89A7-4F7D-B10C-5C1D739F0BA4
P2860
SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@ast
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@en
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@nl
type
label
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@ast
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@en
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@nl
prefLabel
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@ast
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@en
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@nl
P2860
P356
P1476
SCT1 mutants suppress the camp ...... wild-type DNA topoisomerase I.
@en
P2093
M A Bjornsti
P2860
P304
P356
10.1073/PNAS.92.14.6299
P407
P577
1995-07-01T00:00:00Z